Management of cytomegalovirus infection and disease after solid-organ transplantation

Clinical Infectious Diseases

Volumn 33, Issue , 2001, Pages S33-S37

  Van der Bij, W ^a   Speich, R ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOGLOBULIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISOLATION AND PURIFICATION; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; GRAFT REJECTION; MORBIDITY; PRIORITY JOURNAL; SUPERINFECTION; VIRUS DETECTION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSION; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0034985124     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320902     Document Type: Article

References (42)

1. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time
2. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood
3. Comparison of enzyme-linked immunosorbent assay, radioimmunoassay, complement fixation, anticomplement immunofluorescence and passive haemagglutination techniques for detecting cytomegalovirus IgG antibody
4. Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay
5. Screening tests for antibodies to cytomegalovirus: An evaluation of five commercial products
6. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: Correlation with disease
7. Glomerulopathy associated with cytomegalovirus viremia in renal allografts
8. Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci
9. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes
10. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation: A report of 130 consecutive patients
11. A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients
12. Monitoring and diagnosis of cytomegalovirus infection in renal transplantation
13. The cytomegalovirus antigenemia assay: A plea for standardization
14. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction
15. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma
16. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus
17. Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR
18. Evaluation of PCR primers for early diagnosis of cytomegalovirus infection following liver transplantation
19. The polymerase chain reaction, a sensitive and rapid technique for detecting cytomegalovirus infection after renal transplantation
20. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the dernonstration of cytomegalovirus infection after liver transplantation
21. A prospective study of rapid methods of detecting cytomegalovirus in the blood of renal transplant recipients in relation to patient and graft survival
22. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation
23. Monitoring for cytomegalovirus infection in organ transplant recipients: Analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes
24. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: A comparison between the detection of CMV DNAemia by polymerase chain reaction and anti-genemia by CMV pp65 assay
25. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation
26. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: A controlled trial
27. Infection in organ-transplant recipients
28. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation
29. Cytomegalovirus immune globulin prophylaxis in liver transplantation: A randomized, double-blind, placebo-controlled trial
30. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients
31. Prevention of cytomegalovirus-related death by passive immunization: A double-blind placebo-controlled study in kidney transplant recipients treated for rejection
32. Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis
33. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: A meta-analysis
34. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients
35. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
36. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
37. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
38. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
39. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation
40. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients
41. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial
42. Preemptive treatment for the prevention of cytomegalovirus disease: In lung and heart transplant recipients